en Related Fields Related Fields مقاله کامل Full Length/Original Article <strong>Introduction: </strong><em>Rhopalurus junceus </em>scorpion venom has shown potential for anticancer treatment. However, there are no scientific evidence about venom pharmacokinetic (PK) and biodistribution (BD) in tumor-bearing mice. <strong>Methods: </strong>¹³¹I-labeled venom was administrated by intravenous (IV) and oral (PO) routes at the single dose of 12.5 mg/kg. Mice were sacrificed and blood samples, major organs, and tumor were taken at 10, 20, 40, 90, 180, 300, 480, and 1440 min. <strong>Results: </strong>For IV route, maximum peak concentration (C_max), elimination half-lives, total body clearance (CL), distribution volume (V_d), mean residence time (MRT), and area under curve (AUC) were 21.77 &plusmn; 2.45 %Dosis&middot;h/mL, 12.65 &plusmn; 2.1 h, 4.59 &plusmn; 0.23 mL/h, 83.80 &plusmn; 12 mL, 12.49 &plusmn; 2.71 h, and 21.77 &plusmn; 2.45 %Dosis&middot;h/mL, respectively. For&nbsp; PO route, they were 0.60 &plusmn; 0.07 %Dosis&middot;h/mL, 9.33 &plusmn; 1.35 h, 36.94 &plusmn; 4.01 mL/h, 497.33 &plusmn; 30 mL, 12.40 &plusmn; 1.87 h, and 6.89 &plusmn; 1.18 %Dosis&middot;h/mL, respectively. PK parameters (C_max, CL, V_d, and AUC) showed significant differences between IV and PO routes. Bioavailability was 31.6 &plusmn; 4% for PO dose. Kidney, stomach, liver, and lung for IV and stomach, kidney, spleen, and lung for PO routes showed the major uptakes for ¹³¹I-labeled venom. In tumor tissue, after the maximum uptake for both routes, there was a consistent behavior of radioactivity respect to the major organs during the first 480 min. <strong>Conclusion: </strong>The PK and BD of <em>R. junceus</em> venom in mice depend on the administration route. These data represent a starting point for future experiments with this scorpion venom in experimental models of cancer. Intravenous, Mice, Oral administration, Radioactivity, Scorpion venom 287 296 http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-768&slc_lang=en&sid=1 Alexis Díaz-García 0000-0002-7784-7846 Yes Research Department, Laboratories of Biopharmaceuticals and Chemistries Productions (LABIOFAM), Havana, Cuba Gilmara Pimentel González 0000-0001-6345-5844 No Radiopharmacy Laboratory, Oncology and Radiobiology National Institute, Havana, Cuba Tais Basaco Bernabeu 0000-0002-1315-5744 No Radiopharmacy Laboratory, Oncology and Radiobiology National Institute, Havana, Cuba Juan C. Rodríguez Aurrecochea 0000-0002-0708-5399 No Research Department, Laboratory of Experimental pathology, Oncology and Radiobiology National Institute, Havana, Cuba Hermis Rodríguez Sánchez 0000-0002-7753-7055 No Microbiology Department, Cell culture Laboratory, Tropical Medicine Institute “Pedro Kourí”, Havana, Cuba Iraida Sánchez Monzón 0000-0000-0000-0000 No Radiopharmacy Laboratory, Oncology and Radiobiology National Institute, Havana, Cuba Maikel Hernández Gómez 0000-0002-1891-4033 No Radiopharmacy Laboratory, Oncology and Radiobiology National Institute, Havana, Cuba Caridad Rodríguez Torres 0000-0002-1454-5904 No Research Department, Laboratories of Biopharmaceuticals and Chemistries Productions (LABIOFAM), Havana, Cuba Maria Regla Rodríguez Capote 0000-0001-7322-4425 No Research Department, Laboratories of Biopharmaceuticals and Chemistries Productions (LABIOFAM), Havana, Cuba Irania Guevara Orellanes 0000-0002-7994-3137 No Research Department, Laboratories of Biopharmaceuticals and Chemistries Productions (LABIOFAM), Havana, Cuba